LiBBY, short for Life's End Benefits of cannabidiol and tetrahydrocannabinol, was a 12-week trial for agitation in hospice-eligible late-stage dementia. It cut agitation scores but showed more serious infections and deaths on active oil, so adult children face narrow evidence and clear limits. The Alzheimer's Association announced topline results at AAIC 2026 in London on July 14, 2026, in 120 hospice-eligible patients (AAIC 2026 topline announcement). This article explains design, benefit, safety signals, and limits for family decisions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did LiBBY test?
- How large and fast was the benefit?
- What safety signals matter for families?
- Who is outside these results?
- What should you ask the hospice team?
What did LiBBY test?
LiBBY enrolled 120 hospice-eligible patients with dementia and significant agitation across 10 U.S. sites. Study visits occurred in homes or residences, not clinics. The design was randomized, double-blind, and placebo-controlled for 12 weeks. Pennington Biomedical Research Center reports the active oil contained 2 mg THC plus 100 mg CBD taken twice daily (purified-oil dosing summary).
Placebo matched the oil in appearance and schedule. Treatment lasted 12 weeks. Agitation here meant persistent restlessness, aggression, or vocal distress that strains late-stage care. Hospice-eligible means frail enough to qualify for hospice care. Georgetown University School of Medicine places mean age at about 80.
How large and fast was the benefit?
NeurologyLive reports agitation on the Cohen-Mansfield Agitation Inventory fell 6.27 points more with THC/CBD than placebo at week 2 (trial efficacy report). That inventory is a standard checklist for restlessness, aggression, and vocal distress. Separation persisted through week 12.
Neuroscience News reports global improvement favored treatment at 83.9% versus 30.5% on placebo at week 2. By week 12, the gap was 87.2% versus 23.6%. The pattern suggests rapid and durable behavioral change in this group.
What safety signals matter for families?
NeurologyLive reports overall adverse events were similar at 46.7% on THC/CBD versus 42.4% on placebo. Serious adverse events were higher with treatment at 23.3% versus 11.9%. Serious infections drove much of that serious-event gap.
Deaths during the 12-week trial were higher on active treatment at 13.1% versus 5.1% on placebo. Investigators judged no serious adverse event as related to study drug. Frail hospice patients already face high background risk from infection and decline.
Who is outside these results?
Georgetown University School of Medicine notes results apply only to frail, hospice-eligible late-stage patients (Georgetown trial summary). Mean age was about 80 with significant agitation. They do not extend to early memory concerns or milder dementia.
NeurologyLive notes small Phase 2 size, 12-week follow-up, and a single proprietary formula limit wider use. Findings do not establish safety for dispensary or over-the-counter cannabis. Adult products vary in dose, purity, and THC content.
What should you ask the hospice team?
NeurologyLive notes adult children should discuss agitation only with hospice or palliative clinicians. That team knows prognosis, goals, and drug interactions.
Do not substitute a store product for the trial oil. Bring a focused list to the visit: Do not start, stop, or swap any sedative or cannabis product before that visit.
- Ask what may drive agitation now: pain, infection, constipation, sleep loss, or medication change.
- Ask which comfort measures and current prescriptions should change first.
- Ask how the trial oil differs from dispensary and over-the-counter products.
- Bring a full medication list, allergies, falls, and advance-care goals.
You Might Also Like
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Study Design and Evidence Limits for Adult Children
- Implementation-Ready Dementia Interventions in the 2026 NIA Report: What the Findings Mean for Adult Children
- Dementia With Multiple Etiologies in the 2026 NIA Report: What the Findings Mean for Adult Children
